Skip to main content

LENZ Therapeutics, Inc. (LENZ) Stock

LENZ Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

LENZ Therapeutics, Inc. (LENZ), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $11.94. Over the past 52 weeks, it has ranged between $11.48 and $50.40. This places the current price at 23.7% of its 52-week high and 4.0% above its 52-week low. Recent trading volume was recorded at 418,637. The 14-day Relative Strength Index (RSI) stands at 28.74, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $26.99 by 55.76%. Similarly, it is below its 200-day moving average of $30.99 by 61.47%. The MACD histogram is -0.41, indicating bearish momentum (MACD Line: -3.37, Signal Line: -2.96).

52-Week Range

$50.40 - $11.48

-76.31% from high · +4.01% from low

Avg Daily Volume

1,171,571

20-day average

100-day avg: 966,140

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-3.85

Price to Book

1.72

EV/EBITDA

-2.42

EPS (TTM)

-$2.06

Price to Sales

20.87

Q:How is LENZ valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is LENZ's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-151.10%

EBITDA

$-67,695,000

Return on Equity

-28.78%

Return on Assets

-19.52%

Q:How profitable and efficient is LENZ's business model?
0 The operating margin of -151.10% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -28.78% and ROA at -19.52%, the company achieves moderate returns on invested capital.
Q:What are LENZ's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$365.2M

Revenue (TTM)

$17.50M

Revenue/Share (TTM)

$0.63

Shares Outstanding

31.29M

Book Value/Share

$6.78

Asset Type

EQUITY

Q:What is LENZ's market capitalization and position?
LENZ Therapeutics, Inc. has a market capitalization of $365.2M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 31.29M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does LENZ's price compare to its book value?
LENZ Therapeutics, Inc.'s book value per share is $6.78, while the current stock price is $11.94, resulting in a price-to-book (P/B) ratio of 1.76. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$51.29

329.53% upside potential

Analyst Recommendations

Strong Buy

1

Buy

6

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for LENZ?
7 analysts cover LENZ with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $51.29 implies 329.5% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on LENZ?
Current analyst recommendations:1 Strong Buy, 6 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 8, 2026, 02:31 AM

Technical Indicators

RSI (14-day)

28.74

Oversold

50-Day Moving Average

$26.99

-55.76% below MA-50

200-Day Moving Average

$30.99

-61.47% below MA-200

MACD Line

-3.37

MACD Signal

-2.96

MACD Histogram

-0.41

Bearish

Q:What does LENZ's RSI value tell investors?
The RSI (Relative Strength Index) for LENZ is currently 28.74, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret LENZ's MACD and moving average crossovers?
MACD analysis shows the MACD line at -3.37 below the signal line at -2.96, with histogram at -0.41. This bearish crossover indicates downward pressure. The 50-day MA ($26.99) is below the 200-day MA ($30.99), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Dec 25, 2025, 12:33 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for LENZ and get notified when the price changes.

Stay Ahead of the Market with LENZ Therapeutics, Inc. Alerts

Set up price alerts for LENZ Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.